Prestige Consumer Healthcare (PBH) Total Debt (2011 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Total Debt came in at $1.0 billion in Q4 2025, up 4.19% year-on-year from $992.0 million in Q4 2024, and up 4.07% quarter-over-quarter from $993.1 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Total Debt (2011 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Total Debt history runs 15 years deep, the most recent figure standing at $1.0 billion for Q4 2025.
- On a quarterly basis, Total Debt rose 4.19% year-over-year to $1.0 billion in Q4 2025; TTM through Dec 2025 was $1.0 billion, a 4.19% increase from a year earlier, with the FY2025 full-year figure at $992.4 million, down 11.85% from the prior year.
- Total Debt climbed to $1.0 billion in Q4 2025 per PBH's latest filing, from $993.1 million in the prior quarter.
- Across five years, Total Debt topped out at $1.6 billion in Q3 2021 and bottomed at $992.0 million in Q4 2024.
- The 5-year median for Total Debt is $1.3 billion (2023), against an average of $1.3 billion.
- Across the five-year window, Total Debt declined 17.29% in 2024 and increased 4.19% in 2025, its largest moves.
- Year by year, Total Debt stood at $1.5 billion in 2021, then slipped by 6.94% to $1.4 billion in 2022, then retreated by 15.78% to $1.2 billion in 2023, then retreated by 17.29% to $992.0 million in 2024, then increased by 4.19% to $1.0 billion in 2025.
- Per Business Quant, the three latest PBH Total Debt figures stand at $1.0 billion (Q4 2025), $993.1 million (Q3 2025), and $992.7 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 11.45 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.63 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 28.76 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 7.15 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.34 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.81 Bn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 1.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 993.15 Mn |
| Jun 30, 2025 | 992.75 Mn |
| Mar 31, 2025 | 992.36 Mn |
| Dec 31, 2024 | 991.97 Mn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | 1.09 Bn |
| Mar 31, 2024 | 1.13 Bn |
| Dec 31, 2023 | 1.20 Bn |
| Sep 30, 2023 | 1.26 Bn |
| Jun 30, 2023 | 1.32 Bn |
| Mar 31, 2023 | 1.35 Bn |
| Dec 31, 2022 | 1.42 Bn |
| Sep 30, 2022 | 1.44 Bn |
| Jun 30, 2022 | 1.47 Bn |
| Mar 31, 2022 | 1.48 Bn |
| Dec 31, 2021 | 1.53 Bn |
| Sep 30, 2021 | 1.60 Bn |
| Jun 30, 2021 | 1.55 Bn |
| Mar 31, 2021 | 1.48 Bn |